Literature DB >> 7540504

Combined transjugular intrahepatic portosystemic shunt and segmental Lipiodol hepatic artery embolization for the treatment of esophagogastric varices and hepatocellular carcinoma in patients with cirrhosis: preliminary report.

H Sakaguchi1, H Uchida, M Maeda, N Matsuo, K Kichikawa, H Ohishi, H Nishida, K Ueno, K Nishimine, J Rösch.   

Abstract

PURPOSE: To evaluate the feasibility of combining placement of a transjugular intrahepatic portosystemic shunt (TIPS) and transcatheter hepatic segmental artery chemoembolization with Lipiodol (Seg-Lp-TAE) in patients with cirrhosis, esophagogastric varices, and hepatocellular carcinoma (HCC).
METHODS: Five patients with bleeding or large, high-flow esophagogastric varices and HCC were treated by TIPS and Seg-Lp-TAE.
RESULTS: The mean portosystemic pressure gradient decreased from 20.8 cm H2O to 7.8 cm H2O after TIPS. The direct portogram and endoscopic examination revealed reduction of varices. At 6 months, one shunt had functionally occluded and could not be reopened; the other TIPS remained functional. Follow-up CT and the changes of alpha fetoprotein indicated effective therapy of Seg-Lp-TAE for HCC. Four patients are in stabile clinical condition at 9, 6, 1, and 1 months after the combined therapy; one died after 14 months due to decompensated liver cirrhosis.
CONCLUSION: The combined therapy of TIPS and Seg-Lp-TAE will become a new interventional approach for patients with HCC and esophagogastric varices.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540504     DOI: 10.1007/bf02807348

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  10 in total

1.  Role of parallel transjugular intrahepatic portosystemic shunts in patients with persistent portal hypertension.

Authors:  Z J Haskal; E J Ring; J M LaBerge; M Y Peltzer; P M Radosevich; M M Doherty; R L Gordon
Journal:  Radiology       Date:  1992-12       Impact factor: 11.105

2.  Transjugular portal venography and radiologic portacaval shunt: an experimental study.

Authors:  J Rösch; W N Hanafee; H Snow
Journal:  Radiology       Date:  1969-04       Impact factor: 11.105

Review 3.  Conceptual review of the hepatic vascular bed.

Authors:  W W Lautt; C V Greenway
Journal:  Hepatology       Date:  1987 Sep-Oct       Impact factor: 17.425

4.  Transjugular intrahepatic portosystemic shunt: evaluation with Doppler sonography.

Authors:  J M Longo; J I Bilbao; H P Rousseau; L García-Villareal; J P Vinel; J M Zozaya; F G Joffre; J Prieto
Journal:  Radiology       Date:  1993-02       Impact factor: 11.105

5.  Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma.

Authors:  H Uchida; H Ohishi; N Matsuo; K Nishimine; S Ohue; Y Nishimura; M Maeda; T Yoshioka
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

6.  Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment.

Authors: 
Journal:  Ann Surg       Date:  1990-03       Impact factor: 12.969

7.  Segmental transcatheter hepatic artery chemoembolization with iodized oil for hepatocellular carcinoma: antitumor effect and influence on normal tissue.

Authors:  N Matsuo; H Uchida; K Nishimine; S Soda; M Oshima; H Nakano; N Nagano; Y Nishimura; T Yoshioka; Q Guo
Journal:  J Vasc Interv Radiol       Date:  1993 Jul-Aug       Impact factor: 3.464

8.  Segmental embolotherapy for hepatic cancer: keys to success.

Authors:  H Uchida; N Matsuo; H Sakaguchi; N Nagano; K Nishimine; H Ohishi
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Mar-Apr       Impact factor: 2.740

9.  Transjugular intrahepatic portacaval stent shunt: preliminary clinical results.

Authors:  G M Richter; G Noeldge; J C Palmaz; M Roessle; V Slegerstetter; M Franke; W Gerok; W Wenz; E Farthman
Journal:  Radiology       Date:  1990-03       Impact factor: 11.105

10.  Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion.

Authors:  P M Radosevich; E J Ring; J M LaBerge; M Y Peltzer; Z J Haskal; M M Doherty; R L Gordon
Journal:  Radiology       Date:  1993-02       Impact factor: 11.105

  10 in total
  6 in total

1.  Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts.

Authors:  John T Miura; William S Rilling; Sarah B White; Robert A Hieb; Sean M Tutton; Parag J Patel; T Clark Gamblin; Eric J Hohenwalter
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

2.  Transjugular intrahepatic portosystemic shunts in patients with hepatic malignancy.

Authors:  Michael J Wallace; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

3.  Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.

Authors:  Zhu Wang; Hailong Zhang; He Zhao; Xiaoze Wang; Jiaywei Tsauo; Xuefeng Luo; Xiao Li
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

Review 4.  Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law.

Authors:  Gerond Lake-Bakaar; Muneeb Ahmed; Amy Evenson; Alan Bonder; Salomao Faintuch; Vinay Sundaram
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

5.  Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis.

Authors:  Zai-Bo Jiang; Hong Shan; Xin-Ying Shen; Ming-Sheng Huang; Zheng-Ran Li; Kang-Shun Zhu; Shou-Hai Guan
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

6.  Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.

Authors:  Bin Qiu; Meng-Fei Zhao; Zhen-Dong Yue; Hong-Wei Zhao; Lei Wang; Zhen-Hua Fan; Fu-Liang He; Shan Dai; Jian-Nan Yao; Fu-Quan Liu
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.